Entera Bio Ltd. (ENTX) Earnings Call Transcripts

Entera Bio Ltd.'s Latest Earnings Call - April 20, 2026

In the Q1 2026 earnings call for Entera Bio Ltd., management focused on the potential of their lead clinical candidate, EB613, an oral anabolic treatment for osteoporosis. The company highlighted a significant treatment gap in the osteoporosis market, with 92% of gynecologists indicating they would prescribe an oral anabolic if available. Management reiterated their commitment to advancing EB613 into Phase III trials, aiming to address this unmet need. No specific revenue or earnings figures were disclosed during the call, and guidance remains unchanged as the company continues to focus on clinical development.

Reported metrics

Guidance from management

Management did not provide specific financial guidance but confirmed plans to advance EB613 into Phase III trials, indicating a focus on clinical development rather than immediate revenue generation.

What analysts pressed on

Analysts expressed concerns about the competitive landscape for osteoporosis treatments and the challenges in patient adoption of new therapies. There were questions regarding the timeline for Phase III results and the potential for market penetration against established injectable therapies.

Main topics on the call

• EB613 Potential and Market Opportunity — Management emphasized the unique positioning of EB613 as the first oral anabolic treatment for osteoporosis, aiming to democratize access to therapy. CEO Miranda Toledano stated, "Our goal with EB613 is actually to turn ...
• Clinical Data and Efficacy — The Phase II data for EB613 showed promising results, with bone density increments comparable to injectable PTH therapies. Dr. Felicia Cosman noted, "EB613 stimulates bone formation... and suppresses bone breakdown," hig...
• Treatment Gap in Osteoporosis — The call revealed a significant treatment gap, with only 12% of gynecologists currently using injectable anabolic agents. Dr. Goldstein remarked, "92% said if they had an oral agent, they would utilize it," indicating st...
• Phase III Trial Plans — Management outlined plans to initiate Phase III trials for EB613 imminently, focusing on its efficacy as a monotherapy and in sequence with antiresorptive drugs. Toledano stated, "Our goal with this program hasn't wavere...

Read the full Entera Bio Ltd. transcript (April 20, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 12 Entera Bio Ltd. earnings call transcripts on record, spanning March 26, 2020 to April 20, 2026. Based on this history, Entera Bio Ltd. reports semi-annually. The most recent call on file is dated April 20, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

ENTX

Exchange

NasdaqCM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

12

First call

March 26, 2020

Most recent

April 20, 2026

Reporting cadence

semi-annually